Total Funding
58
57
Total FundingGrant raised
Growth Score
-18 pts
Heat Score
-17 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
15383
BioVersys develops novel antibacterial products to combat serious life-threatening infections caused by MDR bacteria.
- Daniel Ritz: Chief Scientific OfficerPast Role: Idorsia, Senior Director and Senior Group Leader Biology
- Marc Gitzinger: CEO & Co-Founder
About the Company
Bioversys AG is a biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. Their focus is on creating therapies to combat multidrug-resistant (MDR) bacterial infections, a major global
health issue. BioVersys’ proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform is designed to identify new treatments by inhibiting bacterial resistance mechanisms, thereby making antibiotics more effective.
